Witold Rużyłło
Institute of Cardiology · 227 works · 27,746 citations · h-index 49
Top works
- Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- Guidelines for Percutaneous Coronary Interventions
- Initial Invasive or Conservative Strategy for Stable Coronary Disease
- Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
- Coronary Intervention for Persistent Occlusion after Myocardial Infarction
- Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
- Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial
- Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome
- Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease
- Gender Differences in the Management and Clinical Outcome of Stable Angina
- Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
- Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology*
- Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
- Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
- Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectoris
- The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina
- A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes
- Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial